55579-01-6

Basic information

• Product Name: 1-PYRIDIN-2-YLMETHYL-PIPERAZINE
• Synonyms: ART-CHEM-BB B004020;BUTTPARK 36\08-66;CHEMBRDG-BB 4101647;1-[(2-PYRIDYL)METHYL]PIPERAZINE;1-PYRIDIN-2-YLMETHYL-PIPERAZINE;1-PYRIDIN-2-YLMETHYL-PIPERAZINE DIHYDROCHLORIDE;(2-PYRIDYLMETHYL)PIPERAZINE;AKOS B004020
• CAS NO: 55579-01-6
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.25
• Product Categories: PIPERIDINE;Amines and Anilines;Heterocycles;piperazines
• Mol File: 55579-01-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 91-93°C 0,4mm
• Flash Point: 124.1 °C
• Appearance: liquid
• Density: 1.073 g/cm³
• Vapor Pressure: 0.00355mmHg at 25°C
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.00±0.10(Predicted)
• CAS DataBase Reference: 1-PYRIDIN-2-YLMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRIDIN-2-YLMETHYL-PIPERAZINE(55579-01-6)
• EPA Substance Registry System: 1-PYRIDIN-2-YLMETHYL-PIPERAZINE(55579-01-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 55579-01-6(Hazardous Substances Data)

Usage

Uses

1-(Pyridin-2-ylmethyl)piperazine is a useful intermediate for the preparation of benzylpiperazine and other piperidine derivatives used as antipsychotic agents and in the treatment of skin related diseases.

InChI:InChI=1/C10H15N3/c1-2-4-12-10(3-1)9-13-7-5-11-6-8-13/h1-4,11H,5-9H2/p+2

Upstream product

• 110-85-0 piperazine 
• 4377-33-7 2-chloromethylpyridine 

Downstream Products

• 77278-93-4 1-(tert-butoxycarbonyl)-4-((2-pyridyl)methyl)piperazine 
• 196300-93-3 1,3-bis[N'-(2-pyridylmethyl)]-N-(piperazidylmethyl)benzene 
• 617691-10-8 4-(4-pyridin-2-ylmethylpiperazin-1-yl)benzonitrile 
• 1277167-58-4 C₂₀H₂₀ClN₅O 
• 149692-12-6 1-(3-((N-phenoxycarbonyl)amino)-3-phenylpropanoyl)-4-((2-methyl-3-pyridyl)cyanomethyl)piperazine 

Relevant articles and documents

Syntheses and structures of N,N′-bis(6-(2-hydroxymethyl)pyridylmethyl)piperazine, its two zinc(II) complexes and the cadmium(II) complex of N-(6-(2-hydroxymethyl)pyridylmethyl)-N′-(2-pyridylmethyl)piperazine

The syntheses and crystal structures of N,N′-bis(6-(2-hydroxymethyl)-pyridylmethyl)piperazine (C18H24N4O2, 3), its polymeric zinc(II) nitrate complex (C18H29N7O14Zn2, 3a) and dinuclear zinc(II) chloride complex (C20H27N5O2Zn2Cl 4, 3b) and mononuclear cadmium(II) nitrate complex of N-(6-(2-hydroxymethyl)pyridylmethyl)-N′-(2-pyridylmethyl)piperazine (C17H22N6O7Cd, 4a) are described. Compound 3 was characterised by 1H and 13C NMR, mass spectrometry and elementary analysis. The structures of all compounds were determined by single crystal X-ray diffraction methods. Crystal data: 3: monoclinic, space group P21/n (no. 14), a=7.816(1), b=6.699(1), c= 16.567(3) A, β=91.94(1)°, V=866.9(2) A3, Z=2; 3a: monoclinic, space group P2/n (no. 13), a=10.274(1), b=11.018(1), C=11.615(1) A, β=93.13(1)°, V= 1312.8(2) A3, Z=2; 3b: triclinic, space group P1 (no. 2), a=9.624(1), b= 11.381(1), c=14.016(1) A, α=106.21(1), β=102.73(1), γ=107.10(1)°, V= 1323.9(2) A3, Z=2; 4a: monoclinic, space group P21/c (no. 14), a=13.589(8), b=9.006(5), c=17.472(8) A, β=101.96(4)°, V=2092(2) A3, Z=4. In the metal complexes, zinc has a distorted square-pyramidal coordination and cadmium has a pentagonal bipyramidal coordination. In 3a and 3b, three coordination sites are occupied by one oxygen and two nitrogens of hexadentate 3 and the remaining two by the bridging hydroxyl group and a terminal water molecule in 3a and by two terminal chlorine atoms in 3b. In 4a, five coordination sites of cadmium are occupied by four nitrogens and one oxygen of the pentadentate ligand, and the remaining two by monodentate nitrate groups. Acta Chemica Scandinavica 1998.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.